Prognostic Role of ERCC1 in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

This publication has 41 references indexed in Scilit:

• Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics
  Journal of Clinical Oncology, 2009
• Targeted therapies in the treatment of advanced/metastatic NSCLC
  European Journal Of Cancer, 2009
• Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer
  Medical Oncology, 2009
• Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature
  Lung Cancer, 2009
• Recommendations from the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast cancer?
  Genetics in Medicine, 2009
• Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
  Lung Cancer, 2008
• Prognostic versus predictive value of biomarkers in oncology
  European Journal Of Cancer, 2008
• ERCC1 mRNA Expression Is Not Associated with Response and Survival after Platinum-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer
  Journal of Thoracic Oncology, 2007
• Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
  Annals of Oncology, 2007
• Measuring inconsistency in meta-analyses
  BMJ, 2003